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Abstract
Background: A direct comparison of prognosis between patients with regional lymph node metastases (LNM) detected
synchronously with the primary melanoma (primary LNM), patients who developed their first LNM subsequently (secondary
LNM) and those with initial LNM in melanoma with unknown primary site (MUP) is missing thus far.
Patients and Methods: Survival of 498 patients was calculated from the time point of the first macroscopic LNM using
Kaplan Meier and multivariate Cox hazard regression analysis.
Results: Patients with secondary LNM (HR= 0.67; p= 0.009) and those with initial LNM in MUP (HR= 0.45; p= 0.008) had a
better prognosis compared to patients with primary LNM (median survival time 52 and 65 vs. 24 months, respectively). A
high number of involved nodes, the presence of in-transit/satellite metastases and male gender had an additional
independent unfavourable effect.
Conclusions: Survival of patients with LNM in MUP and with secondary LNM is similar and considerably more favourable
compared to those with primary LNM. This difference needs to be considered during patient counselling and for
stratification purposes in clinical trials. The assumption of an immune privilege of patients with MUP which is responsible for
rejection of the primary melanoma, and results in a favourable prognosis is not supported by our data.
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Introduction
The prognosis of melanoma patients with loco-regional
metastasis varies considerably with 5-year survival rates ranging
between 29% and 51.6% [1]. The American Joint Committee on
Cancer (AJCC) 2009 staging system includes the number of
tumour-bearing nodes, the tumour burden at the time of lymph-
node staging (microscopic vs. macroscopic), ulceration of the
primary melanoma and the presence of in-transit or satellite
metastasis to assign patients to the prognostic sub-stages IIIA-C
[2]. The sub-stage is of major relevance with regards to patient
selection for adjuvant therapies, planning of surveillance programs
and for stratification purposes in clinical trials [3,4]. Moreover, the
assignation to a sub-stage is used for patient counselling and
prognosis prediction [5,6].
The AJCC stage III classification is exclusively based on the
analysis of patients with cutaneous melanoma and lymph node
metastasis (LNM) already present at the time of the initial
melanoma diagnosis (referred to as primary LNM) [2,7].
Nevertheless, the same stage III classification algorithm is also
applied for stage I/II patients at the time point when loco-regional
metastasis occur in the years after initial diagnosis (referred to as
secondary LNM). Differences in prognosis were previously
reported in patients with primary vs. secondary LNM but only
small selected cohorts were analyzed [8,9]. Moreover, differences
of prognosis between patients with primary and secondary LNM
might be assumed based on the observation that a long disease-
free interval was found to be prognostically favourable for the
subsequent course of disease in patients with recurrences [10–13].
The occurrence of metastases in the absence of an apparent
primary tumour in 2% to 10% of melanoma cases is still an
unexplained phenomenon.[14–16] One hypothesis is that an
initially unrecognized primary melanoma regressed over time
through immunological rejection [17] and is therefore not
detectable at the time of melanoma diagnosis based on histopa-
thology of a excised palpable node [18]. In several studies a more
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favourable prognosis was observed in MUP patients compared to
those with known primary tumour [19–23]. A comparison
between all three situations (primary LNM vs. secondary LNM
vs. initial LNM in MUP) by Sondak et al. showed poorer survival
of patients with primary LNM, as presented at annual meeting of
ASCO 2010 but not yet published in detail [24].
The present study aimed to investigate prognostic factors of
melanoma patients at the time of the first nodal macro-metastasis
to identify potential differences between patients with metastases
already present at initial melanoma diagnosis, those who




All had given their written informed consent to have clinical
data recorded by the Central Malignant Melanoma Registry
(CMMR) registry. The institutional ethics committee Tu¨bingen
approved the study (identifier 144/2013R).
Patients
Patients with cutaneous melanoma and nodal metastasis treated
between 1996 and 2010 at the University Department of
Dermatology in Tu¨bingen, Germany, were identified in the
Central Malignant Melanoma Registry (CMMR) database which
prospectively records patients from more than 60 dermatological
centers in Germany. The aims and methods of data collection by
the CMMR have previously been reported in detail [3,4,25]. Of
792 patients with follow-up those initially presenting with micro-
metastases only detected in sentinel node biopsy (294 patients)
were excluded after individual file review resulting in a final
sample size of 498.
Data obtained for each patient included gender, age at diagnosis
of nodal disease, the situation (primary LNM vs. secondary LNM
vs. initial LNM in MUP), presence of satellite/in-transit lesions,
the number of involved nodes (1 vs. 2 or 3 vs. 4 or more) after the
initial lymph node staging procedures, the date of the initial
diagnosis and the last follow-up, and the date and cause of death, if
applicable. The following characteristics of the primary tumour
were analyzed: body site (axial vs. extremities), Breslows tumour
thickness, Clarks level of invasion (I-III vs. IV, V), ulceration, and
subtype (superficial spreading melanoma vs. nodular melanoma vs.
lentigo maligna melanoma vs. acral lentiginous melanoma).
Statistical Analysis
Follow-up time was defined from the date of diagnosis of the
first lymph node metastasis to the date of last follow-up or death.
Estimates of cumulative survival probabilities according to
Kaplan-Meier were described together with 95% confidence
intervals and compared using two-sided log-rank test statistics.
Median survival times (MST) are presented. For the analysis of
disease-specific survival patients who were alive at the last follow-
up or died without evidence of metastatic melanoma were
censored.
Multivariable Cox proportional hazard models were used to
determine independent prognostic factors. Categorized variables
were dummy coded to adhere to the linearity assumption of
multivariable regression analysis. All characteristics described
above were considered in multivariable analysis. Missing values
were assessed independently as a separate group to allow the
assessment of patients with MUP. Forward and backward stepwise
procedures of the multivariable modelling process were conducted.
Results of the Cox models were described by means of hazard
ratios (HR) together with 95% confidence intervals (95% CI), p-
values were based on the Wald test. Confounding was assessed by
checking the effect of each remaining non-significant variable,
which was not in a model, on factors in the model. If changes in
the estimate of factors in the model of 5% or more occurred the
variable was considered a confounder. Differences in the
distribution of variables according to the situation at first
occurrence of metastasis were calculated by Fishers exact test.
Throughout the analysis, p values less than 0.05 were considered
as statistically significant. All statistical analyses were carried out
using the SPSS Version 19 (IBM SPSS, Chicago, Illinois, USA).
Results
Patients
Patients characteristics are shown in Table 1. A total of 498
melanoma patients (58% male) were included in the survival
analysis at the time of initial stage III diagnosis. The median age
was 59 years (inter quartile range [IQR] 47–70 years). The
median follow-up time for patients who died was 20 months (IQR
11–35) and 58 months (IQR: 25–104) for patients who were alive
at the last date of observation. The median survival time according
to Kaplan Meier (MST) was 42 months. Cumulative survival rates
were 65.0% (2 years), 44.4% (5 years) and 36.1% (10 years).
64.1% of patients developed the first nodal metastasis after the
excision of the primary melanoma in contrast to 22.2% who
already presented with metastases at the initial diagnosis and
13.7% had an unknown primary tumour. Significant differences
were observed between these subpopulations regarding gender,
tumour thickness and ulceration of the primary melanoma, sub-
stage and the presence of satellite/in-transit metastasis (Table 1).
Survival Analysis of Patients with Lymph Node
Metastases
In bivariate analysis, shorter survival was observed in patients
with more than one involved lymph node (Figure 1A), if in-transit/
satellite metastases were present (Figure 1B) and in male patients.
Multivariate analysis showed that the impact was strongest in
patients with more than 3 lymph node metastases (HR=2.2;
p,0.001) or 2–3 lymph node metastases (HR=1.6; p = 0.002)
followed by the presence of in-transit metastases (HR=1.6;
p = 0.012) and male gender (HR=1.4; p = 0.023). Interestingly,
patients with secondary LNM and MUP patients had a
considerably better prognosis compared to initially metastasized
patients with known primary tumour both in bivariate (Table 2)
and multivariable analysis (Table 3). The median survival time
(MST) was 24 months for patients with primary LNM, 52 months
for those with secondary LNM and 65 months for MUP,
respectively (Figure 1C). Age, body site and histopathological
characteristics of the primary melanoma did not influence survival
according to our analysis (Table 2).
Discussion
We confirmed the important prognostic role of the number of
involved nodes and the presence of in-transit/satellite metastases
in our study of melanoma patients with macroscopic lymph node
metastases. In contrast to others, we also included stage I/II
patients who relapsed to the lymph nodes in the years after the
initial melanoma diagnosis and patients with unknown primary
melanoma in our study. Only 51% of all 792 stage III patients
with nodal disease treated at our institution between 1996 and
2011 presented with LNM at the time of initial diagnosis, while
Prognosis of Melanoma with Lymph Node Metastasis
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40% represent relapsed stage I/II patients and 9% were patients
with melanoma of unknown primary.
We found that patients with secondary LNM had a better
prognosis (HR 0.67; p= 0.009) compared to patients with LNM
detected at the time of primary melanoma excision as described
before [8,9]. Multivariate analysis, which was performed to
investigate the relative impact of different prognostic factors and
their interaction by confounding showed that the impact on
prognosis was independent from all other analysed factors. This
was of major importance as differences in the distribution of other
variables were detected between patients with primary LNM,
secondary LNM and MUP (Table 1). The observation that a long
disease-free interval before recurrence is associated with a
favourable subsequent course of disease provides further indirect
evidence that the timing of lymph node involvement might be
relevant for prognosis [10–13,25,26]. Disparate results about the
influence of this time interval were only reported in a minority of
studies [27–29]. There are different possibilities to explain a
favourable survival of patients with secondary vs. primary LNM:
(a) the disease-free interval might reflect differences in the biologic
behaviour and aggressiveness of tumour cells suggesting a
favourable prognosis of patients with secondary LNM [30].
Table 1. Patient characteristics of 498 patients with lymph node metastases.







N % % % % p#
Age at stage III diagnosis 0.136
,50 years 150 30.1 23.4 31.0 36.8
50–59 years 100 20.1 16.2 20.4 25.0
60–69 years 119 23.9 26.1 24.5 17.6
$70 years 129 25.9 34.2 24.1 20.6
Gender 0.024
Male 291 58.4 67.6 53.9 64.7
Female 207 41.6 32.4 46.1 35.3
Tumour thickness ,0.001
,1.00 mm 83 20.3 7.6 29.3
1.00–1.99 mm 102 24.9 6.7 29.3
2.00–3.99 mm 114 27.9 33.3 27.3
$4.00 mm 110 26.9 52.4 14.1
na 89
Ulceration ,0.001
Yes 153 39.3 38.5 68.8
No 236 60.7 61.5 31.2
na 109
N stage 0.059
N1b 238 49.3 38.0 53.7 46.9
N2b 113 23.4 25.9 21.9 26.6
N3 132 27.3 36.1 24.4 26.6
na 15
Number of involved lymph nodes 0.365
1 265 55.1 48.6 58.1 51.6
2–3 131 27.2 31.8 24.5 32.8
4 or more 85 17.7 19.6 17.4 15.6
na 17
Sub-stage ,0.001
IIIB 165 40.3 24.0 48.6 na*
IIIC 244 59.7 76.0 51.4 na*
na 89
Metastases
LNM only 438 55.4 79.3 91.5 85.3 0.003
LNM plus satellite/In-transit metastases 60 7.6 20.7 8.5 14.7
#p-value indicating differences in distribution according to the situation at first occurrence of metastasis (missing values are not considered).
*not classified due to missing ulceration data. na =missing values; LNM= lymph node metastasis; MUP=melanoma of unknown primary.
doi:10.1371/journal.pone.0066953.t001
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Patients with primary LNM might have a more aggressive type of
tumour, which is capable of metastasizing early. This is supported
by the observations of a higher tumour thickness and a higher
frequency of additional satellite/in-transit metastasis in patients
with primary LNM. These patients might also have a worse
prognosis in the subsequent course of the disease. In contrast,
having ‘‘silenced’’ tumour cells growing to clinically detectable
metastases only after several years might be prognostically
favoured even after loco-regional metastasis has occurred.
Ulceration of the primary melanoma was mainly observed in
patients with secondary LNM, but only present in a subpopulation
of patients in LNM already detected at the time-point of initial
diagnosis (68.8% vs. 38.5%; p,0.001). Even if ulceration had not
prognostic impact in the entire patient cohort its significant
correlation with secondary lymph node metastasis was unexpected
and indicates its biologic relevance, which needs to be further
investigated in future studies.
(b) The favourable prognosis of relapsed stage I/II patients
might reflect the efficiency of surveillance programs aiming at
early detection of recurrences in the years after excision of the
primary melanoma. Recent studies found a survival benefit for
patients under surveillance beyond lead time bias [3]. Neverthe-
less, the differences in survival between patients with primary and
secondary LNM or MUP could also be influenced by other factors
not considered in our study. Tumour growths dynamics repre-
sented by the tumour doubling time [31] and/or mitotic activity
and the host immune response e.g. the intensity of the lymphocytic
infiltrate in melanoma tissue [32] might be relevant for prognosis
as well and could be differentially distributed between the
subpopulations. An analysis of these histopathological features
was not performed because tissue blocks were not available.
Our patients with initial lymph node metastasis but unknown
primary melanoma had a better prognosis than patients with
primary LNM and known primary tumour (HR=0.45; p = 0.008).
This is in contrast to a few prior reports [33–35] but in agreement
with most other publications in this field [19–22]. Moreover,
prognosis of MUP patients resembles that of patients with
secondary LNM (Figure 1C). There is only one study by Sondak
et al. comparing primary LNM, secondary LNM and initial lymph
node metastasis in MUP in a comprehensive analysis, implying
very similar findings, but thus far detailed data have not been
published [24].
The comparison of these three clinical situations regarding
prognosis might help to understand the phenomena of MUP. A
regression zone is frequently observed in primary tumours and
complete regressions of primary melanomas as postulated in MUP
could occasionally be demonstrated [36,37]. The reasons for
regression of the primary tumour are incompletely understood but
an effective immune response directed against melanoma cells was
suggested as an explanation for local regression [17]. Whether or
not this immune response might be systemically relevant and
beneficial for the further course of disease in these patients is
unclear, because underestimation of the tumour thickness due to
regression hampers the investigation of its prognostic impact [37].
Lee et al [19] and Prens et al [21] both demonstrated a clear
survival advantage of patients with MUP after therapeutic
lymphadenectomy compared to patients with known primary
tumour and explained this observation with a strong endogenous
immune response directed against melanoma resulting in both
regression of the primary tumour and a better outcome. On the
other hand, Shaw et al. suggested that the immune response
leading to regression does not reflect a privilege but is a secondary
activation of the immune system indicating metastatic spread of
melanoma cells to the lymph nodes [38].
We agree that MUP might be regarded as a combination of a
regressed primary melanoma with the subsequent occurrence of
secondary lymph node metastasis. But on the other hand, patients
with MUP and those with secondary LNM but known primary
tumour had a similar survival in our study. The comparison of
Figure 1. Survival according to Kaplan Meier. Differences were
observed according to the number of lymph node metastases (LNM) (A)
and presence or absence of in-transit or satellite metastases (B). Survival
is more favourable for patients with secondary LNM or lymph node
metastases but unknown primary tumour (MUP) compared to patients
with primary LNM (C).
doi:10.1371/journal.pone.0066953.g001
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prognosis between these two situations according to our analysis is
not suggestive for a clinically relevant immune advantage in MUP
and in agreement with prior studies [16,39].
Ulceration had no impact on prognosis in our patients. This is
in agreement with the stage III analysis of Balch et al. finding
ulceration and other histopathological characteristics to be less
important prognostic markers in patients with macroscopic nodal
disease compared to those with micro-metastases only [1]. A
favourable prognosis of melanoma patients at the time of the first
nodal metastasis was associated with female gender in bivariate
and multivariable analyses. Interestingly, this association was
limited to patients with secondary LNM and MUP. It was not
Table 2. Survival analysis of 498 patients with palpable lymph node metastases based on Kaplan Meier.
Factor n % % Dead
5 Year survival rate
[95%-CI*] (%)
10 Year survival rate
[95%-CI*] (%) p**
Gender 0.012
Male 291 58.4 55 38.9 [32.6; 45.2] 31.4 [24.5; 38.3]
Female 207 41.6 45.4 52.0 [44.4; 59.6] 42.8 [34.0; 51.6]
Age 0.382
,60 years 250 50.2 54.4 42.2 [35.3; 49.1] 33.7 [26.4; 41.0]
.= 60 years 248 49.8 47.6 46.8 [39.7; 53.9] 38.9 [30.7; 47.1]
Body site of primary 0.562
Axial 226 45.4 52.2 43.5 [36.4; 50.6] 36.4 [28.4; 44.4]
Extremities 204 41.0 51 43.3 [35.5; 51.1] 37.3 [29.3; 45.3]
Missing data/unknown primary 68 13.7 47.1 50.2 [36.5; 63.9] 34.0 [18.7; 49.3]
Ulceration of the primary 0.054
Not ulcerated 236 47.4 48.7 47.4 [40.3; 54.5] 42.2 [34.6; 49.8]
Ulcerated 153 30.7 53.6 38.3 [30.7; 45.9] 31.2 [21.2; 41.2]
Missing data/unknown primary 109 21.9 52.3 46.0 [35.4; 56.6] 31.1 [19.7; 42.5]
Histologic subtype of primary 0.228
SSM 197 39.6 48.7 47.5 [39.9; 55.1] 42.4 [34.4; 50.4]
Nodular 119 23.9 58.0 40.6 [32.6; 48.6] 30.6 [19.6; 41.6]
LMM 19 3.8 47.4 53.6 [29.3; 77.9] 42.9 [15.9; 69.9]
ALM 45 9.0 53.3 21.9 [3.5; 40.3] 0.0 [0.0; 0.0]
Missing data/unknown primary 118 23.7 47.5 46.8 [36.4; 57.2] 35.3 [23.1; 47.5]
Clark’s level of invasion 0.364
Level I–III 99 19.9 50.5 45.5 [34.9; 56.1] 41.6 [30.6; 52.6]
Level IV–V 243 48.8 52.3 43.6 [32.6; 54.6] 35.3 [27.5; 43.1]
Data Missing/unknown primary 156 31.3 49.4 44.9 [35.9; 53.9] 33.5 [23.3; 43.7]
Breslow’s thickness of primary 0.186
,2 mm 185 37.1 49.7 47.0 [39.2; 54.8] 40.6 [32.0; 49.2]
.= 2 mm 224 45.0 53.1 40.2 [31.6; 48.8] 33.9 [26.1; 41.7]
Missing data/unknown primary 89 17.9 48.3 48.7 [36.7; 60.7] 34.5 [21.4; 47.6]
Situation at first occurrence of metastasis 0.001
Primary LNM 111 22.2 62.2 28.0 [18.2; 37.8] 25.8 [16.0; 35.6]
Secondary LNM 319 64.1 48.0 48.7 [38.9; 58.5] 41.0 [34.3; 47.7]
Initial LNM but MUP 68 13.7 47.1 50.2 [36.5; 63.9] 34.0 [18.7; 49.3]
Satellite or Intransit metastasis 0.008
Present 60 12.0 65.0 31.0 [17.9; 44.1] 19.7 [6.2; 33.2]
Absent 438 88.0 49.1 46.2 [32.7; 59.7] 38.3 [32.4; 44.2]
Number of involved lymph nodes ,0.001
1 265 53.2 43.8 51.5 [44.8; 58.2] 44.5 [36.9; 52.1]
2–3 131 26.3 58.0 36.6 [29.0; 44.2] 29.3 [19.3; 39.3]
4 ore more 85 17.1 62.4 30.7 [19.3; 42.1] 16.4 [4.8; 28.0]
Missing data 17 3.4 52.9 54.8 [29.7; 79.9] 45.6 [19.1; 72.1]
*95%-CI = 95% confidence interval;
**p-values are results of log rank tests excluding cases with missing values.
LNM= lymph node metastasis; MUP =melanoma of unknown primary.
doi:10.1371/journal.pone.0066953.t002
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observed in our patients with primary palpable LNM as described
by others [1]. In general, there are conflicting results regarding the
prognostic role of gender in loco-regionally metastasized patients
in the literature [27,40–43]. Our results are similar to those
reported by Nowecki et al., who analyzed prognostic factors in 286
melanoma patients after therapeutic lymphadenectomy and found
that a high number of involved nodes, an extracapsular lymph
node involvement and male gender were independently associated
with poor survival. They observed a better survival in patients with
metastasis occurring later than 24 months after excision of the
primary melanoma compared to those with metastases appearing
earlier, but did not include patients with MUP [12].
Conclusion
A high number of involved nodes, the presence of additional in-
transit/satellite metastases and male gender were negative
predictors of survival after occurrence of macroscopic lymph node
metastasis including patients with unknown primary tumour and
those with secondary LNM. In contrast to patients with known
primary melanoma who already presented with lymph node
metastases at initial diagnosis, prognosis in both other groups was
more favourable (MST 65 months for MUP and 52 months for
secondary LNM vs. 24 months for primary LNM). This difference
needs to be considered for patient counselling and for stratification
purposes in clinical trials. The assumption of an immune
advantage in patients with MUP which is responsible for rejection
of the primary melanoma and results in a more favourable
prognosis is not supported by our data, as prognosis of patients
with MUP is similar to that of stage I/II patients with recurrent
nodal disease.
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